Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2010
12/02/2010US20100303814 Antibodies Against a Cancer-Associated Epitope of Variant HNRNPG and Uses Thereof
12/02/2010US20100303813 Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
12/02/2010US20100303812 Neutralizing monoclonal antibody against human dll4
12/02/2010US20100303811 Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
12/02/2010US20100303810 Method for treating lupus
12/02/2010US20100303809 Methods for the detection and quantitation of pten
12/02/2010US20100303808 Humanized anti-cd20 antibodies and methods of use
12/02/2010US20100303807 Methods for the treatment of il-1beta related diseases
12/02/2010US20100303806 Avian derivedantibodies
12/02/2010US20100303805 Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
12/02/2010US20100303804 Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol
12/02/2010US20100303803 Catenate for immunostimulation
12/02/2010US20100303802 Antibody directed to g protein coupled receptors (gpcr)
12/02/2010US20100303801 Host cell specific binding molecules capable of neutralizing viruses and uses thereof
12/02/2010US20100303760 Treatment and/or prevention of cancer and/or arthritis
12/02/2010US20100303758 Novel Glucocorticoid Receptor Agonists
12/02/2010US20100303756 Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
12/02/2010US20100303736 Anti-il-9 antibody formulations and uses thereof
12/02/2010US20100303726 Humanized collagen antibodies and related methods
12/02/2010US20100303723 Drug delivery systems using fc fragments
12/02/2010US20100303721 Use of Parasitic Biological Agents for Diseases Prevention and Control
12/02/2010US20100303720 VARIANTS OF HUMANIZED ANTI-CARCINOMA MAb CC49
12/02/2010US20100303719 Anti-cancer compounds
12/02/2010US20100303718 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials
12/02/2010US20100303717 Stabilized Uncoated Particles of Reversed Liquid Crystalline Phase Materials Cross Reference to Related Applications
12/02/2010US20100303716 Switchable nano-vehicle delivery systems, and methods for making and using them
12/02/2010US20100303715 Prostate-specific membrane antigen and uses thereof
12/02/2010CA2799608A1 Amino acid sequences which enhance peptide conjugate solubility
12/02/2010CA2763950A1 Use of 2 anti-sparc antibodies to predict response to chemotherapy
12/02/2010CA2763641A1 Expression of recombinant proteins
12/02/2010CA2763569A1 Albumin-amyloid peptide conjugates and uses thereof
12/02/2010CA2763493A1 Antigen-binding proteins
12/02/2010CA2763488A1 Antigen-binding proteins
12/02/2010CA2763486A1 Casb7439 constructs
12/02/2010CA2763469A1 Antigen-binding proteins
12/02/2010CA2763446A1 Stem cell targeting
12/02/2010CA2763440A1 Assays for influenza virus hemagglutinins
12/02/2010CA2763161A1 Cardiovascular related uses of il-1.beta. antibodies and binding fragments thereof
12/02/2010CA2763115A1 Stim2-mediated capacitive calcium entry
12/02/2010CA2762934A1 Cdc45l peptides and vaccines including the same
12/02/2010CA2762653A1 Immunomodulatory agent-polymeric compounds
12/02/2010CA2762650A1 Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
12/02/2010CA2762647A1 Nanocarriers possessing components with different rates of release
12/02/2010CA2762260A1 Extraneous agents testing
12/02/2010CA2762203A1 Simian adenovirus 41 and uses thereof
12/02/2010CA2761817A1 Production of glycoproteins
12/02/2010CA2761280A1 Modulators for her2 signaling in her2 expressing patients with gastric cancer
12/02/2010CA2761233A1 Tri- or tetraspecific antibodies
12/02/2010CA2760757A1 Compositions and methods for antibodies targeting complement protein c3b
12/01/2010EP2256205A1 Porphorymonas gingivalis polypeptides and polynucleotides
12/01/2010EP2256204A1 Porphorymonas gingivalis polypeptides and polynucleotides
12/01/2010EP2256203A1 IL-23 and its receptor; related reagents and methods
12/01/2010EP2256202A2 Stimulus-inducible i (kappa)b kinase ikk signalsome
12/01/2010EP2256199A1 Therapeutic uses of BR43X2 soluble receptors
12/01/2010EP2256185A1 Heterologous protection against pasteurella multocida provided by p. multocida fur cells and the outer-membrane protein extracts thereof
12/01/2010EP2256132A1 Method of detecting proBNP with a monoclonal antibody binding to the amino acids 38-44
12/01/2010EP2255831A1 Liposome based diepitope constructs
12/01/2010EP2255828A1 Methods of therapy for cancers expressing the CD40 antigen
12/01/2010EP2255827A1 Vaccines comprising aluminium adjuvants and histidine
12/01/2010EP2255826A2 Neisserial vaccine compositions comprising a combination of antigens
12/01/2010EP2255820A1 Use of parasitic biological agents for prevention and control of autoimmune diseases
12/01/2010EP2255789A1 Virosome-like-particles
12/01/2010EP2254911A1 HUMANIZED ANTI-C5aR ANTIBODIES
12/01/2010EP2254909A1 NON-AGGREGATING HUMAN Vh DOMAINS
12/01/2010EP2254903A2 Escherichia coli immunogens with improved solubility
12/01/2010EP2254596A2 METHODS OF MODULATING THE ORGANIC SOLUTE AND STEROID TRANSPORTER (OST alpha -OST beta) ACTIVITY AND TREATING ASSOCIATED CONDITIONS
12/01/2010EP2254595A1 Methods and compositions for reducing the impact of enteric diseases
12/01/2010EP2254594A1 Process for stabilizing an adjuvant containing vaccine composition
12/01/2010EP2254593A2 Immunogenic influenza composition
12/01/2010EP2254592A2 Mhc multimers in borrelia diagnostics and disease
12/01/2010EP2254571A2 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
12/01/2010EP1725583B1 Methods for increasing protein polyethylene glycol (peg) conjugation
12/01/2010EP1648502B1 Hcv vaccines
12/01/2010EP1572077B1 Uses of monoclonal antibody 8h9
12/01/2010EP1569679B1 Chaperonin 10 immunosuppression
12/01/2010EP1513552B1 Packaged virus-like particles in combination with cpg for use as adjuvants with allergens : method of preparation and use
12/01/2010EP1449850B1 Human cdr-grafted antibodies and antibody fragments thereof
12/01/2010EP1427441B1 COMPOSITE SUPERIMMUNOGEN FOR BI-FUNCTIONAL VACCINE Tat-gp160 FOR USE IN THE TREATMENT OF AIDS
12/01/2010EP1423425B1 Receptor, the use thereof, and mouse antibodies
12/01/2010EP1414861B1 Humanized antibodies against icam-1, their production and uses
12/01/2010EP1372706B1 Proteosome-liposaccharide vaccine adjuvant
12/01/2010EP1319089B1 In vitro assay for measuring the immunogenicity of a vaccine
12/01/2010EP1284137B1 Nonoral preparation having three-layer structure
12/01/2010EP1244790B1 Nucleic acids encoding polypeptides having chips activity
12/01/2010CN1997352B Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
12/01/2010CN1951495B Nano target medicine for magnetothermal therapy of malignant tumor
12/01/2010CN1928112B Expression of VEGF I type receptor on blood vessel adventitia fibroblast
12/01/2010CN1852734B Consensus/ancestral immunogens
12/01/2010CN1824675B Neisserial antigens
12/01/2010CN1809584B Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof
12/01/2010CN1763181B Vaccine against mumps containing a JERYL-LYNN virus strain
12/01/2010CN1727362B Preparation and application of vaccine for curing tumor in positive carcino-embryonic antigen
12/01/2010CN1694715B Use of beta glucan particles and antibodies in preparing medicine for cancer therapy
12/01/2010CN1646154B Albumin-fused anti-angiogenesis peptides
12/01/2010CN1464789B Vaccine against the influenza virus and method for producing said virus vaccine
12/01/2010CN101903529A SM-protein based secretion engineering
12/01/2010CN101903514A Peptides that can bind to scurfin and uses thereof
12/01/2010CN101903406A Bivalent, bispecific antibodies
12/01/2010CN101903405A Bivalent, bispecific antibodies
12/01/2010CN101903404A Bivalent, bispecific antibodies
1 ... 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 ... 1823